Evidence map›Paper›PMID 40585843›Full record

ArticleWorld journal of clinical oncology2025

Demographic trends in mortality due to ovarian cancer in the United States, 1999-2020.

Laiba Razaq, Arkadeep Dhali, Rick Maity, Abdul Rafae Faisal, Ali Shan Hafeez, Asad Zaman, Mohammad Abdullah Humayun, Muhammad Faizan, Mavra Shahid, Mamoona Majeed and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Laiba RazaqDepartment of Internal Medicine, Akhtar Saeed Medical and Dental College, Lahore 54000, Pakistan.
Arkadeep DhaliAcademic Unit of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield S5 7AU, United Kingdom. arkadipdhali@gmail.com.
Rick MaityDepartment of General Medicine, Institute of Post Graduate Medical Education and Research, Kolkata 700020, India.
Abdul Rafae FaisalDepartment of Internal Medicine, CMH Multan Institute of Medical Sciences, Multan 59070, Pakistan.
Ali Shan HafeezDepartment of Internal Medicine, CMH Multan Institute of Medical Sciences, Multan 59070, Pakistan.
Asad ZamanDepartment of Internal Medicine, CMH Multan Institute of Medical Sciences, Multan 59070, Pakistan.
Mohammad Abdullah HumayunDepartment of Internal Medicine, Shalamar Institute of Health Sciences, Lahore 54840, Pakistan.
Muhammad FaizanDepartment of Internal Medicine, Hamad Medical Corporation, Doha 3050, Qatar.
Mavra ShahidDepartment of Internal Medicine, Akhtar Saeed Medical and Dental College, Lahore 54000, Pakistan.
Mamoona MajeedDepartment of Internal Medicine, Akhtar Saeed Medical and Dental College, Lahore 54000, Pakistan.
Pramod SinghDepartment of Internal Medicine, Barhabise Primary Health Care Centre, Barhabise 45302, Nepal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian carcinoma has the highest mortality rate among all gynecological cancers. Several reproductive and hormonal risk factors, including early menarche, late menopause, limited use of oral contraceptives, and a low pregnancy rate, have been identified as contributors to the increased susceptibility to ovarian cancer. Advancements in cancer therapy over the past century, including the emergence of precision oncology, underscore the importance of early detection and tailored interventions, factors particularly critical in ovarian cancer, where late-stage diagnosis remains a persistent barrier to survival. This challenge is compounded by the lack of a universally endorsed screening program, resulting in late-stage identification and widespread metastasis.

aimTo evaluate demographic differences in ovarian cancer-related mortality from 1999 to 2020 among adult females aged ≥ 25 years within the United States.

methodsCenters for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database was used to collect de-identified death certificate data for malignant neoplasm of the ovaries related deaths in female adults aged 25 years and older from the year 1999 to 2020. Crude mortality rates and age-adjusted mortality rates (AAMRs) per 100000 people were calculated. Join point regression program was used to assess annual percent changes in mortality trends, with statistical significance set at

resultsBetween 1999 and 2020, 337619 deaths due to ovarian cancer occurred among United States females aged 25 to > 85. The AAMR decreased from 14.62 in 1999 to 10.15 in 2020, with significant declines across various demographics. The AAMRs were highest among non-Hispanic White women,

conclusionThe mortality trends for ovarian carcinoma patients showed an overall decrease, with the highest mortality rates observed among older individuals (65 to > 85 years) and non-Hispanic Whites. These disparities underscore the need for equitable healthcare access and targeted policy interventions.

Indexed as

Age-adjusted mortality rateCrude mortality rateDemographic trendsMortalityOvarian cancerOvarian carcinomaUnited States

Identifiers

PMID40585843
PMCPMC12198854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.